Latest "Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined" News Stories

16:02 EST 12th December 2018 | BioPortfolio

Here are the most relevant search results for "Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined" found in our extensive news archives from over 250 global news sources.

More Information about Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined for you to read. Along with our medical data and news we also list Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined Clinical Trials, which are updated daily. BioPortfolio also has a large database of Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined Companies for you to search.

Showing "Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined" News Articles 1–25 of 2,400+

Wednesday 12th December 2018

DuPont Nutrition & Health Helps to Reduce Health Risks for Overweight Consumers

New Findings from Clinical Study Show Link between Metabolic Health Benefits of HOWARU® Shape and Gut Microbiome WILMINGTON, Del. (PRWEB) December 12, 2018 DuPont Nutrition & Health has released new findings from a clinical study of a synbiotic dietary supplement that gives hope to overweight consumers at risk of health complications. Combining the benefits of a proven probiotic with a p...

Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced it has entered into a collaboration agreement with the Paul Turner Lab at Yale University to manufacture and supply therapeutic bacteriophage (ph...

RURO Announces Limfinity® ML - Machine Learning Module for Limfinity®

RURO, Inc., a leading provider of LIMS, LIS, RFID and other life science software solutions, announces the Limfinity® ML (Machine Learning) addition for its Limfinity® 7 framework. FREDERICK, Md. (PRWEB) December 12, 2018 RURO, Inc., a leading provider of LIMS, LIS, RFID and other life science software solutions, announces the Limfinity® ML (Machine Learning) addition for its Limfi...

Seeing the Big Picture: Transform Diabetes Care With the AGP

How do you keep blood glucose levels in range in patients with diabetes? First you have to spot the areas of variability, says Dr Bergenstal. Medscape Diabetes & Endocrinology

Tuesday 11th December 2018

Japan Pharma Climbing Aboard Digital Health Train, But Not Up To Speed?

The still somewhat loosely defined concept of 'digital health' continues to take concrete forms through recent deals in Japan, where...    

Chickens to be marker of Anthropocene

(University of Leicester) New research shows the age of man -- the Anthropocene -- will be defined by the chicken.

GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation

Standard Life UK Smaller Companies (SLS) - Disciplined approach driving outperformance

Edison Investment Research - Investment Companies - Standard Life UK Smaller Companies: Standard Life UK Smaller Companies (SLS) is managed by Harry Nimmo at Aberdeen Standard Investments. He has followed the same investment process since he took over management of the trust in 2003, through a number of economic cycles, and considers it to be stable, predictable and well defined, while providing a...

Streck Inc Product Pipeline Analysis, 2018 Update [Report Updated: 06122018] Prices from USD $750

SummaryStreck Inc Streck is a developer and manufacturer of hematology, immunology and molecular biology products for clinical and research laboratories. The company provide products such as offers body fluid, sedimentationrate, chemistry, whole blood, whole blood glucose and hemoglobin, instruments and consumables, antibiotic resistance kits, reagents and thermometers. It also provides laboratory...

Bioxyne Ltd BXN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryBioxyne Ltd Bioxyne, is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC lactobacillus fermentum. It also develops a range of existing functional food and bea...

Mologic Ltd Medical Equipment Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryMologic Ltd Mologic is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company provides products such as bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit, among others. It offers expertise such as clinical research, chemistry, chronic obstructive pulmonary disea...

Team Novo Nordisk Adds Five New Riders to 2019 Pro Roster

The world’s first all-diabetes pro cycling team brings in an Olympian and advances four riders from its development squad while adding changes to its GSG-designed jersey ATLANTA (PRWEB) December 11, 2018 Team Novo Nordisk, the world’s first all-diabetes pro cycling team, will race its seventh season with 16 athletes from a dozen countries. The five new riders joining the team include Olympian...

Versant Ventures Launches Black Diamond Therapeutics

Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively from founding investor Versant Ventures. Black Diamond is the first company ...

Millions of Low-Risk Type 2 Diabetes Patients May Be Over-Testing

A new study finds that one in seven individuals with type 2 diabetes who don't use insulin and are at low risk of hypoglycemia monitor their blood glucose levels more often than recommended. Medscape Medical News

Hardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales

Hardman & Co Research 11-Dec-2018 / 07:15 GMT/BST Hardman & Co: Accelerating into fiscal 2019 with first sales genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specifi...

Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupusbased on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11th 2018 - 7:30 am CET - Neovacs (Euronext Growth Paris: ALNEV), leader in the field of active immune therapy for the treatment of autoimmune-diseas

Monday 10th December 2018

Many Patients with Diabetes Routinely Check Their Blood Glucose — Even When Recommendations Say They Shouldn't

Many adults with type 2 diabetes check their blood glucose levels multiple times daily — even if they aren't taking medications associated with hypoglycemia — according to...

Are T2D Patients Monitoring Blood Glucose Needlessly?

(MedPage Today) -- Claims data suggest 1 in 7 patients do unnecessary daily fingersticks

Axonics® Announces Publication of NICE Briefing

The U.K.’s National Institute for Health and Care Excellence Published a Medtech Innovation Briefing on the Axonics r-SNM® System Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of...

ALung Announces Significant Progress in its Hemolung Clinical Trial Programs

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of major milestones in its clinical trial programs. In the United States, nearly thirty hospitals have been brought online for ALung’s VENT-AVOID Trial...

Nucelis Partners with Darwin to Build Business in China; Signs First Development Agreement

Nucelis, the microbial strain development subsidiary of agriculture biotech company, Cibus, today announced a partnership agreement with Nanjing Darwingenetech Co, Ltd (Darwin) to jointly identify and enter into agreements with China based customers for Nucelis’ proprietary gene-editing and advanced fermentation expertise to improve fermentation yields a...

NICE Wins Two Prestigious ASTORS’ Awards for Best Investigation and Best 911 Incident Recording and Analytics Solutions

2018 marks the third consecutive year that NICE has received awards for NICE Inform and NICE Investigate NICE (Nasdaq: NICE) announced today that it has been recognized with two ‘ASTORS’ Awards for NICE Inform and NICE Investigate. Sponsored by American Security Today, the ‘ASTORS’ Awards recognize outstanding product developme...

KOKUYO's "360° Gliding Chair ing" Wins FRAME Awards ORGATEC 2018 in Two Categories

KOKUYO starts European expansion auspiciously with the good designed and health conscious office chair. KOKUYO Co., Ltd. (TOKYO:7984), a leading provider of office design and furniture in Japan, won FRAME Awards for "360º Gliding Chair ing" in two categories at ORGATEC 2018, “Trade Fair Sta

BMS and Vedanta announce a new clinical collaboration to evaluate OPDIVO (nivolumab) and VE800

Bristol-Myers Squibb and Vedanta announce a clinical trial collaboration to evaluate BMS' programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with Vedanta s VE800, a rationally defined human bacterial consortium, in patients with advanced or metastatic cancers

Hardman & Co Research: Avacta (AVCT): Wake-up call for the market

Hardman & Co Research 10-Dec-2018 / 07:30 GMT/BST Hardman & Co: Wake-up call for the market Avacta (AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical and commercial benefits of Affimers are being recognised increasingly through ...

Quick Search


News Quicklinks